12/22/2025
๐ Breaking: AstraZeneca inks a blockbuster $2B global licensing deal with Jacobio Pharma for their Pan-KRAS inhibitor JAB-23E73!
This game-changer targets KRAS-mutated cancers (think pancreatic, colorectal, lung) โ mutations in ~23% of all cancers. AstraZeneca gets exclusive rights outside China, with Jacobio pocketing $100M upfront + up to $1.915B milestones + royalties. Joint ops in China.
JAB-23E73, from Jacobio's induced allosteric platform, is already in Ph1 trials (US/China) showing early promise. Huge validation for KRAS innovation โ Jacobio's stock? Up 600%+ YTD!
Oncology pipeline just leveled up. What's next for Big Pharma in targeted therapies?
๐ Breaking: AstraZeneca inks a blockbuster $2B global licensing deal with Jacobio Pharma for their Pan-KRAS inhibitor JAB-23E73!
This game-changer targets KRAS-mutated cancers (think pancreatic, colorectal, lung) โ mutations in ~23% of all cancers. AstraZeneca gets exclusive rights outside China, with Jacobio pocketing $100M upfront + up to $1.915B milestones + royalties. Joint ops in China.
JAB-23E73, from Jacobio's induced allosteric platform, is already in Ph1 trials (US/China) showing early promise. Huge validation for KRAS innovation โ Jacobio's stock? Up 600%+ YTD!
Oncology pipeline just leveled up. What's next for Big Pharma in targeted therapies?
Send a message to learn more